News

August 2016

Draft PIC/S Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments

Geneva, 10 August 2016: PIC/S has published on a draft basis a guidance on Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (PI 041-1 (Draft 2)) developed by the PIC/S Working Group on Data Integrity. This draft guidance will be applied on a 6-month trial basis by PIC/S Participating Authorities. This draft document results from the need among Inspectorates to have access to harmonised Data Integrity guidance, considering the impact to public health. The purpose of the trial-period is to learn from implementation. It is acknowledged that the guidance requires expanding in some areas; however, the document has value in describing foundational principles which can be enhanced in future revisions. This draft document is not open for comments by industry. Formal adoption of the guidance will proceed in accordance with PIC/S procedures - including possibly an industry consultation - on a revised version after completion of the trial-period.

To download the draft guidance (PI 041-1 (Draft 2)), please consult the page “Publications” or click on the link below:

November 2019

Draft PIC/S Recommendation on How to Evaluate / Demonstrate the Effectiveness of a Pharmaceutical Quality System in relation to Risk-based Change Management

Geneva, 28 November 2019: PIC/S has published on a draft basis a Recommendation on How to Evaluate / Demonstrate the Effectiveness of a Pharmaceutical Quality System in relation to Risk-based Change Management (PI 054-1 (Draft 1)) developed by the PIC/S Expert Circle on Quality Risk Management (QRM).

This draft Recommendation will be applied on a 6-month trial basis by PIC/S Participating Authorities.

The purpose of this draft document is to provide guidance on evaluating and demonstrating the effectiveness of a PQS in relation to risk-based change management. This is in recognition of the fact that the PIC/S GMP Guide requires companies to demonstrate the effectiveness of their PQS and to apply quality risk management (QRM) principles to change control activities. Further information on the background to this Recommendation and the anticipated benefits of this guidance are provided in PIC/S Concept Note (PS/INF 88/2019).

This draft document is not open for comments by industry. Formal adoption of the guidance will proceed in accordance with PIC/S procedures on a revised version after completion of the trial-period.

To download the draft Recommendation (PI 054-1 (Draft 1)) and the Concept Note (PS/INF 88/2019), please consult the page “Publications” or click on the links below:

September 2019

Focused stakeholders consultation on revised draft PIC/S GMP Guide Annex 2A (Manufacture of Advanced Therapy Medicinal Products for Human Use) and Annex 2B (Manufacture of Biological Medicinal Substances and Products for Human Use)

Geneva, 20 September 2019: A draft revision of the PIC/S GMP Guide Annex 2 (Manufacture of biological medicinal substances and products for human use) has been prepared by the PIC/S Working Group on revision of Annex 2 established with WHO, led by Francesco Cicirello, Australia / TGA, and by the PIC/S Sub-Committee on GMDP Harmonisation, led by Paul Gustafson, Health Canada. 

This revision is subject to a focused stakeholder consultation which includes both consultation questions and an opportunity to comment on: 

  • a draft Annex 2A (PS/INF 25/2019 (Rev. 1)): Manufacture of Advanced Therapy Medicinal Products for Human Use; and
  • a draft Annex 2B (PS/INF 26/2019 (Rev. 1)): Manufacture of Biological Medicinal Substances and Products for Human Use. 

Draft Annex 2A takes into account the international development in the regulation of Advanced Therapy Medicinal Products (ATMP) with particular attention to the European Commission guideline on GMP for ATMP which has been published since the latest revision of the EU Annex 2, while addressing at the same time concerns of PIC/S Participating Authorities with regard to patient safety and proportionate regulation for ATMPs. Draft Annex 2B is the revised version of EU Annex 2 for biologics (excluding ATMPs). 

This consultation will also allow PIC/S to collect feedback from stakeholders to help PIC/S develop its thinking in this area. PIC/S recognises that this is a rapidly developing industry and the revision being developed represents an intention of PIC/S to consider: 

   -    issues that stakeholders including (academia, hospitals, subject matter experts or the pharmaceutical industry SMEs)
        are facing in the international context; and

   -    how harmonised international GMP standards can help to facilitate manufacturing of these products, especially in
        consideration of the increasing manufacturing that occur cross-border. 

The consultation period will last 3 months and run from 20 September 2019 to 20 December 2019.

To submit feedback, please provide feedback exclusively on the dedicated Consultation Notice (PS/INF 24/2019) and submit in Word format (not PDF) by e-mail with subject line "PIC/S Focused Public Consultation – Revision Annex 2" to one of the following associations which will collect and compile responses. Stakeholders should only reply once. 

To download the Consultation Notice (PS/INF 24/2019) and the Draft Annexes 2A and 2B (PS/INF 25/2019 (Rev. 1) and PS/INF 26/2019 (Rev. 1)) please consult the page “Publications” or click on the links below:

PS INF 24 2019 Consultation Notice Revision Annex 2

PS INF 25 2019 (Rev. 1) Draft Annex 2A (Manufacture of ATMP) to PICS GMP Guide for Public Consultation.pdf

PS INF 26 2019 (Rev. 1) Draft Annex 2B (Manufacture of biological medicinals) to PICS GMP Guide for Public Consultation.pdf

May 2019

PIC/S meetings in Geneva, Switzerland, 8-10 April 2019

Geneva, 21 May 2019: the PIC/S Committee met on 9-10 April 2019 in Geneva (Switzerland), preceded by a meeting of the PIC/S Executive Bureau on 8-9 April 2019.

The press release regarding these meetings is available in newsletter format here or can be downloaded in pdf format from the link below:

May 2019

2019 PIC/S Seminar (Toyama, Japan)

Geneva, 20 May 2019: Registrations for the 2019 PIC/S Seminar on "Quality Assurance of Sterile Medicinal Products - PIC/S GMP Guide Annex 1" (Toyama, 13-15 November 2019) are now open (for Medicines Regulatory Authorities only).

More

Seminar 2019 logo

The 2019 PIC/S Annual Seminar on "Quality Assurance of Sterile Medicinal Products - PIC/S GMP Guide Annex 1" will be hosted by Japan's Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medicinal Devices Agency (PMDA) in Toyama (Japan) from 13-15 November 2019.

The Seminar will focus on Quality Assurance of Sterile Medicinal Products - PIC/S GMP Guide Annex 1 and will consist of interactive discussions, presentations and workshops. It will be an ideal opportunity for both novice and experienced inspectors to enhance their inspection skills through knowledge sharing and discussion. This Seminar is intended to provide a further understanding of PIC/S GMP Guide Annex 1 based on issues discussed during its ongoing revision and through a case study of sterility assurance. The Seminar will also allow participants to acquire skills on how to make risk based decisions during GMP inspections. Workshops will be supported by the use of videos of practical manufacturing operations in order to stimulate active discussions.

Registrations to the PIC/S Seminar 2019 are now open (for Medicines Regulatory Authorities only).

For more information and registration click here

March 2019

Bangladesh applies for PIC/S pre-accession

Geneva, 5 March 2019: On 26 February 2019, Bangladesh's Directorate General of Drug Administration (DGDA) applied for PIC/S pre-accession. The Rapporteurs will be appointed at the next PIC/S Committee meeting in Geneva (Switzerland) on 9-10 April 2019.